

EXHIBIT 67

```
UNITED STATES DISTRICT COURT
1
          FOR THE NORTHERN DISTRICT OF OHIO
                  EASTERN DIVISION
2
3
     IN RE: NATIONAL
                             )
                                MDL No. 2804
4
     PRESCRIPTION
     OPIATE LITIGATION
                                Case No.
5
                                1:17-MD-2804
                             )
6
     THIS DOCUMENT RELATES ) Hon. Dan A.
                             ) Polster
7
     TO ALL CASES
8
               WEDNESDAY, AUGUST 1, 2018
9
      HIGHLY CONFIDENTIAL - SUBJECT TO FURTHER
10
                CONFIDENTIALITY REVIEW
11
               Videotaped deposition of Nathan J.
12
    Hartle, held at the offices of Covington &
13
    Burlington, LLP, One City Center, 850 Tenth
14
    Street Northwest, Washington, DC, commencing
15
    at 9:03 a.m., on the above date, before
16
    Carrie A. Campbell, Registered Diplomate
17
18
    Reporter, Certified Realtime Reporter,
     Illinois, California & Texas Certified
19
    Shorthand Reporter, Missouri & Kansas
20
21
    Certified Court Reporter.
22
              GOLKOW LITIGATION SERVICES
          877.370.3377 ph | 917.591.5672 fax
23
                    deps@qolkow.com
24
25
```


Highly Confidential - Subject to Further Confidentiality Review




Highly Confidential - Subject to Further Confidentiality Review



Highly Confidential - Subject to Further Confidentiality Review



Highly Confidential - Subject to Further Confidentiality Review



America is the deadliest drug epidemic on 1 record in our country's history? 2 I'm not an epidemiologist, but 3 Α. I would believe, yes. Okay. Well, let's look at 5 Ο. 1437.3, which we will mark as Exhibit 41 --6 7 42. (McKesson-Hartle Exhibit 42 8 marked for identification.) 9 OUESTIONS BY MR. RAFFERTY: 10 11 34 Okay. And it appears, though 16 Q. this one does have a date on it, it's 17 September 29, 2017. So not really all that 18 long ago, right? 19 Correct. 20 Α. 21 Q. Okay. Less than a year ago, 22 right? That is. 23 Α. And you see down there Nate 24 Q. Hartle, senior director, regulatory affairs, 25

1 right? Yeah, it's my document. 2 Α. Okay. Do you recall giving 3 Q. this presentation? 4 5 Α. I do. MR. RAFFERTY: If we could, 6 7 let's turn to .3, Corey. 8 QUESTIONS BY MR. RAFFERTY: 9 You see that up in the top of Q. 10 one of your slides there on page 3, a headline, "Deadliest Drug Epidemic on Record 11 in Our Nation's History"? 12 13 Do you see that? 14 Α. Yep. 15 You wouldn't have put that in Q. your presentation unless you thought it was 16 17 true, right? 18 Α. No. 19 So you don't dispute that, Q. 20 right? 21 Α. I do not. 22 Okay. It then goes on and Q. says, "The drug problems of past decades pale 23 when compared to the current opioid epidemic 24 which has killed 165,000 Americans from 2000 25

1 to 2014." 2 Did I read that right? You did. Α. 3 Okay. Once again, you agree 4 Q. with that statement, right? 5 These are part of the 6 Α. 7 presentation that I gave. If we now go to the next 8 Q. Okay. page, page 4, it says over there, "Scope of 9 the problem." On an average day, an average 10 day in the US, more than 650,000 opioid 11 12 prescriptions are dispensed. Do you see that? 13 14 I do. Α. 3,900 people initiate 15 Q. non-medical use of prescription opioids, and 16 then it says 580 people initiate heroin use. 17 You see that? 18 19 Α. I see those. And in fact, opioid abuse and 20 Q. 21 addiction is a gateway to heroin use and 22 addiction, correct? MS. HENN: Objection to form. 23 I'm not a medical THE WITNESS: 24 25 expert, but, you know, I've read

things, I use data from different 1 sources, and they say that. 2 OUESTIONS BY MR. RAFFERTY: 3 I don't -- okay. As head of 4 Q. 5 regulatory affairs and the controlled substance monitoring program for national 6 chains of McKesson, would you agree that in 7 fact narcotic painkiller abuse, opioid abuse, 8 is a gateway to heroin use? 9 MS. HENN: Objection to form. 10 THE WITNESS: I would agree 11 12 that it can be, yeah. OUESTIONS BY MR. RAFFERTY: 13 Okay. And in fact, 78 people 14 die from an opioid-related overdose every day 15 according to your slide. 16 17 Do you see that? I see that. 18 Α. In fact, if you go on to your 19 Q. presentation, page 16, .16, talking about the 20 heroin use, it says -- or what you say in 21 your presentation, or what you put in your 22 presentation, was people who are addicted 23 to -- and then it says, "Opioid painkillers 24 are 40 times more likely to be addicted to 25

1 heroin." 2 Do you see that? 3 Α. I see that. And you agree with that? 4 Q. 5 Α. I put them in the slides as part of the information that I keep current 6 7 on. 8 You agree with that? Q. 9 Α. Again, I'm not an expert in terms of numbers, but I agree with what 10 11 they're putting out. 12 Okay. Q. 13 Α. The concepts --And you wouldn't have put it 14 Ο. out there if you thought it was inaccurate, 15 16 right? I would not have. 17 18 Okay. Talking about the Q. heroin, the gateway to heroin, if we could, 19 let's have 1580. 20 (McKesson-Hartle Exhibit 43 21 22 marked for identification.) 23 QUESTIONS BY MR. RAFFERTY: This is another presentation 24 Q. that you gave, Mr. Hartle. We'll mark this 25

as Exhibit 43. This is another presentation 1 that you gave. If you look at this --2 MR. RAFFERTY: Corey, if you 3 could pull it up, please, 1.580 --5 1.1580. All right. Just give me the 6 I'll just use the Elmo. 7 QUESTIONS BY MR. RAFFERTY: 8 9 You see there it says, Q. "Regulatory affairs update, RNA leadership 10 team, Nate Hartle, senior director, 11 regulatory affairs." 12 Do you see that? 13 14 Α. Yes. November 20, 2015. 15 Q. 16 You see that? 17 Α. I do. Okay. Do you recall giving 18 Q. this presentation? 19 I'm going to scan through it 20 Α. real quick just so I can refresh --21 Well, let me -- and feel free 22 Q. 23 to, but I'm just going to -- I'm going to start with the second page, so... 24 I -- I believe it was a 25 Α.

Highly Confidential - Subject to Further Confidentiality Review

